Rozenman Mary M. 4
4 · Aimmune Therapeutics, Inc. · Filed Mar 5, 2018
Insider Transaction Report
Form 4
Rozenman Mary M.
See Remarks
Transactions
- Sale
Common Stock, $0.0001 par value
2018-03-01$33.10/sh−1,807$59,812→ 129 total - Exercise/Conversion
Stock Option (right to buy)
2018-03-01−1,807→ 105,436 totalExercise: $3.02Exp: 2025-04-17→ Common Stock (1,807 underlying) - Exercise/Conversion
Common Stock, $0.0001 par value
2018-03-01$3.02/sh+1,807$5,461→ 1,936 total
Footnotes (2)
- [F1]The sales reported in the Form 4 were effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- [F2]The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from February 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.